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Abstract
Background: Colon cancer is the third most commonly diagnosed cancer and the second leading cause of cancer
mortality worldwide. Chalcone and its derivatives are reported to exhibit anti-cancer effects in several cancer cell
lines, including colon cancer cells. In addition, chalcones have advantages such as poor interaction with DNA and
low risk of mutagenesity. In our previous study, a group of chalcone derivatives were synthesized and exhibited
strong anti-inflammatory activities. In this study, we evaluated the anti-cancer effects of the chalcone derivative,
L2H17, in colon cancer cells.
Methods: The cytotoxicities of L2H17 on various colon cancer cell lines were investigated by MTT and clonogenic
assay. Cell cycle and apoptosis analysis were performed to evaluate the molecular mechanism of L2H17-mediated
inhibition of tumor growth. Also, scratch wound and matrigel invasion experiments were performed to estimate the
cell migration and invasion after L2H17 treatment. Finally, we observed the anti-colon cancer effects of L2H17 in vivo.
Results: Our data show that compound L2H17 exhibited selective cytotoxic effect on colon cancer cells, via inducing
G0/G1 cell cycle arrest and apoptosis in CT26.WT cells. Furthermore, L2H17 treatment decreased cell migration and
invasion of CT26.WT cells. In addition, L2H17 possessed marked anti-tumor activity in vivo. The molecular mechanism of
L2H17-mediated inhibition of tumor promotion and progression were function through inactivated NF-κB and Akt
signaling pathways.
Conclusions: All these findings show that L2H17 might be a potential growth inhibitory chalcones derivative for colon
cancer cells.
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Background
Colon cancer is the third most commonly diagnosed
cancer and the second leading cause of cancer mortality
worldwide [1]. Although the mortality rate is decreasing
as the result of improved detection, the incidence of
colon cancer continues to increase [2]. The development
of colon cancer is a complicated process, including com-
plex interactions among genetic alterations, environmen-
tal carcinogens, and host immune system [3]. There is
increasing evidence that chronic inflammation is an
important pathogenic factor in the initiation and pro-
gression of colon cancer. For example, inflammatory
bowel disease is an important risk factor for the develop-
ment of colon cancer [4].
Chalcone is an important secondary plant metabolite
which shows an array of pharmacological properties
[5]. In addition, chalcones have been reported to ex-
hibit several biological activities, including anti-tumor,
anti-inflammatory, immunomodulatory, anti-bacterial,
anti-malarial, anti-leishmanial, trypanocidal and nitric
oxide inhibitory activity [6, 7]. Synthetic analogs and
derivatives of the molecule are increasingly getting into
focus due to their promising therapeutic potential.
Chalcone derivatives are reported to exhibit anti-
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cancer effects in several cancer cell lines, such as
human acute leukemia cells [8], colon cancer cells [9,
10], human bladder cancer cells [11], and lung cancer
cells [12]. In addition, as anticancer therapeutic agents,
chalcones have advantages such as poor interaction
with DNA and low risk of mutagenesity [13].
In our previous study, a group of chalcone derivatives
were synthesized and screened for anti-inflammatory activ-
ities. Some of the compounds, including L2H17, L40H37,
L6H21, and L48H37 exhibited excellent anti-inflammatory
effects in LPS-stimulated macrophages (structures of these
chalcone derivatives are shown in Fig. 1a) [14]. A lot of
studies have revealed that there is an association between
inflammation and cancer development [15]. Thus, we hy-
pothesized that these chalcone derivatives may exhibit anti-
cancer effect in colon cancer cells. In the present study, we
show that L2H17 possesses the best anti-tumor effect on
colon cancer cell lines and lowest cytotoxicity on noncan-
cerous cell among these four compounds. Further biological
experiments of L2H17 on its anti-tumor effects in vitro and
in vivo, the molecular mechanisms of L2H17-mediated
inhibition of tumor promotion and tumor progression were
then examined. The findings obtained here may help us to
develop novel plant-derived chalcones used for potent
chemotherapeutic agents against colon cancer.
Methods
Cell lines and reagents
SW620 (human colon cancer cell line), HCT 116 (human
colon cancer cell line), CT26.WT (mouse colon cancer cell
line), and HL-7702 (human hepatocytes) were obtained
from Shanghai Institute of Biosciences and Cell Resources
Center (Chinese Academy of Sciences, Shanghai, China)
and cultured in RPMI-1640 or DMEM (Gibco/BRL life
Technologies, Eggenstein, Germany), with 10 % heat-
inactivated FBS (Gibco/BRL life Technologies, Eggenstein,
Germany), 1 % penicillin/streptomycin solution (Mediatech
Inc., Manassas, VA) in a humidified atmosphere of 5 %
CO2 at 37 °C. Antibodies for IκB-α, cleaved PARP-1, Akt1/
2, Bax, Bcl-2, procaspase-3, E-cadherin, lamin B, goat anti-
rabbit IgG-HRP, mouse anti-goat IgG-HRP, and donkey
anti-goat IgG-HRP were obtained from Santa Cruz Bio-
technology (Santa Cruz, CA); and antibodies for GAPDH,
cleavaged caspase-3 and p-Akt were obtained from Cell
Signaling Technology (Danvers, MA). FITC Annexin V
apoptosis Detection Kit I was purchased from BD
Pharmingen (Franklin Lakes, NJ). Matrigel was from
BD Biosciences (Shanghai, China). Mitomycin C was
purchased from Sigma (Louis, MO). Chalcone deriva-
tives were synthesized and characterized as described
in our previous publication [14]. Compounds with a purity
of 98.9 %, were dissolved in DMSO for in vitro experi-
ments, and were dissolved in 1 % sodium carboxyl methyl
cellulose-Na (CMC-Na) for in vivo experiments.
Animals
Female BALB/c mice weighing 18–20 g were obtained
from the Animal Center of Wenzhou Medical University
(Wenzhou, China). Animals were housed at a constant
room temperature with a 12:12 h light-dark cycle, and
fed with a standard rodent diet and water. The animals
were acclimatized to the laboratory for at least 3 days
before used. Protocols involving the use of animals were
approved by the Wenzhou Medical University Animal
Policy and Welfare Committee (Approval documents:
wydw2014-0062).
MTT assay
Cells (5 × 103 cells/well) were seeded in 96-well plates
for 24 h and then treated with chalcone derivatives or
curcumin with different doses (1, 3, 10, 30 or 100 μM)
for 48 h, while DMSO was used as the vehicle control.
After treatment, a fresh solution of MTT (5 mg/mL)
prepared in phosphate buffer solution (PBS) was added
to the cells in each well for 4 h at 37 °C. Then the MTT
was aspirated, and the formazan crystals resulting from
mitochondrial enzymatic activity on the MTT substrate
were dissolved with 150 μL of DMSO; absorbance at
490 nm was recorded by the multiwell-plate reader at
490 nm. Each experiment was done in triplicate, and
repeated for three times; the mean of the three values
from three independent experiments was determined,
and the results were expressed as percent of the vehicle
control. IC50 values of each compounds was calculated
by GraphPad Pro 5.0 (San Diego, CA).
Dynamic monitoring of CT26.WT cell proliferation using
the RT-CES system
The dynamic monitoring of CT26.WT cell proliferation
after treatment was performed using the ET-CES system
(Acea Biosciences Inc., San Diego, CA). CT26.WT cells
were plated at a density of 6 × 104 cells/well in 300 μL of
medium in 8 well E-plates and the installed plates were
placed in a standard cell culture incubator, at 37 °C in a
humidified atmosphere of 5 % CO2 overnight. After cell
seeded, the integrated software was used to record and
analyze the data during 0-100 h. And L2H17 or curcu-
min at different concentrations (0, 1, 3, 10, 30, 100 μM)
was added to the medium at 24 h after incubation. The
cell index represents the quantitative measure of the
spreading and/or proliferative status of the cells in an
electrode-containing well.
Clonogenic assay
Cells were seeded in 6-well plates (500 cells/well) in 3 mL
of RPMI-1640 medium at 37 °C in 5 % CO2 atmosphere
overnight. L2H17 (1, 3, or 10 μM), curcumin (10 μM) or
vehicle (DMSO) was added to the cells for 7 days. The
culture medium was replaced by the fresh drug-
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containing medium every two days to keep cells growing
for 7 days. Colonies were washed with PBS, fixed with 4 %
methanol at room temperature for 15 min, washed with
purified water for 3 times and stained with Crystal violet
for 10 min. Colonies containing more than 50 cells were
counted, and visualized colonies were then photographed
and calculated. Each experiment was done in triplicate for
three independent experiments.
Cell cycle analysis
CT26.WT cells (5 × 105 cells/well) were seeded in 6-well
plates and allowed to adhere overnight. The nest day, the
cells were treated with L2H17 (1, 3, 10 and 30 μM), curcu-
min (30 μM) or vehicle (DMSO) for 24 h. Then the cells
were trypsinized, washed, and fixed in 75 % ice-cold etha-
nol at -20 °C overnight. After centrifugation, the pellets
were washed with cold PBS, suspended in 500 μL PBS with
50 mg/ml propidium iodide (PI) and incubated at 37 °C for
40 min in the dark. The cell cycle distribution was deter-
mined using Becton Dickinson FACSCalibor (Franklin
Lakes, NJ) and analyzed by ModFit LT (Verity Software
House, Topsham, ME). Each experiment was done in tripli-
cate for four independent experiments.
Cell apoptosis analysis
CT26.WT cells (5 × 105 cells/well) were seeded in 6-well
plates and allowed to adhere overnight, and then treated
with L2H17 (1, 3, 10 and 30 μM), curcumin (30 μM), or
vehicle (DMSO) 48 h. The cells were harvested and
stained with Annexin V and PI. Flow-cytometric analysis
was performed using FACScalibor. All experiments were
repeated for four times.
Scratch wound model
CT26.WT cells (5 × 105 cells/well) were seeded in 6-well
plates and allowed to adhere overnight. At 80–90 %
confluence, “reference line” was scratched at the bottom
of the plate using a sterile 10 μL pipette tip. After being
washed with PBS thrice, cells were further incubated
with L2H17 (10 μM), curcumin (10 μM) or vehicle
(DMSO) in the presence of mitomycin C (8 μg/ mL) in
calcium-free RPMI-1640 to study the cell migration in
the absence of cell proliferation. Photomicrographs of
cells migrating across the “reference line” were taken in
different fields after each treatment at 0, 24 and 48 h
with a Canon digital camera (Canon Inc., Tokyo, Japan),
respectively. The rate of mobility was quantified by the
migrated distance of cells moved from the “reference
lines” toward the center as compared to control. All
experiments were repeated for four times.
Matrigel invasion assay
The effects of L2H17 on invasion of CT26.WT cell were
studied by a modified Boyden chamber Matrigel method
using 24-well Transwell plates with 8 μm pore size
(Corning Costar Corp, Shanghai, China) coated with
10 μL Matrigel (diluted 1:9 with serum-free medium,
BD Biosciences, Shanghai, China). In brief, 5 × 105
CT26.WT cells suspended in 200 μL serum-free RPMI
1640 culture medium were plated into the upper
Matrigel-coated chamber, and then L2H17 (1, 3, or
10 μM), curcumin (1, 3, or 10 μM), or vehicle (DMSO)
was loaded to the cell suspension. The bottom chamber
was loaded with 500 μL of RPMI 1640 medium contain-
ing 10 % FBS, and the cells were then allowed to invade
for 24 h at 37 °C. The cells that invaded into the bottom
chamber were fixed in 1 % methanol for 15 min, stained
with crystal violet for 25 min, and washed with PBS for
three times. The images were visualized under a light
microscope (×100; Nikon, Tokyo, Japan) and photo-
graphed. All experiments were independently repeated
for four times. Total number of invaded cells was
counted and presented as the ratio of the numbers of
invasive cells compared to that of DMSO control.
Western blot assay
After treated with L2H17, curcumin, or vehicle (DMSO),
CT26.WT cells were harvested and lysed, supernatants
were collected. The protein concentration was determined
and balanced with purified water. After the sample loading
buffer was added, 80 μg of protein samples were electro-
phoresed and then transferred to nitrocellulose membranes
(Bio-Rad Laboratories, Hercules, CA). Each membrane
was blocked at room temperature for 1.5 h and incu-
bated with specific primary antibodies for 2 h at room
temperature and at 4 °C overnight. After incubated
with horseradish peroxidase-conjugated secondary
antibodies for 1 h, the immunoreactive bands were
visualized using enhanced chemiluminescence reagents
(Bio-Rad Laboratories, Hercules, CA). The amounts of
the proteins were analyzed using ImageJ analysis soft-
ware version 1.38e (National Institutes of Health,
(See figure on previous page.)
Fig. 1 Chalcone derivatives reduced viability of colon cancer cells. (a) Structures of curcumin and chalcone derivatives. Colon cancer cell lines,
such as SW620 (b), HCT116 (c), CT26.WT (d), and human hepatocytes HL-7702 cells (e) were treated with chalcone derivatives (L2H17, L40H37, L6H21,
or L48H37) or curcumin at various concentrations (1, 3, 10, 30, or 100 μM) for 48 h, while DMSO was used as the vehicle control. After 48-h treatment,
the cell proliferation of each group was assessed by MTT assay. The data were obtained from three independent experiments performed in triplicate,
and the results were expressed as percentage of vehicle (DMSO) control. The data were presented as mean ± SEMs, and fitted with GraphPad Prism
5.0 to obtain the IC50 values
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Bethesda, MD) and normalized to their respective
controls.
Preparation of nuclear extracts
Nuclear protein extraction from CT26.WT cells were
obtained by using nuclear protein extraction kit (Beyotime
Biotech, Nantong, China) according to the manufacturer’s
instructions. The nuclear extract (30 μg protein) was used
for the western blot analysis.
In vivo anti-tumor study
CT26.WT cells were harvested and injected intravenously
into the BALB/c mice (3 × 105 cells/mouse, in 200 μL of
RPMI-1640). Simultaneously, the mice were administered
orally with either L2H17 (25 mg/kg/day or 50 mg/kg/day),
curcumin (50 mg/kg/day or 100 mg/kg/day), or vehicle
(1 % CMC-Na) for 60 days, while the tumor-free control
mice were treated with the L2H17 (50 mg/kg/day), curcu-
min (100 mg/kg/day), or 1 % CMC-Na as the negative
control (n = 9 in each group). The survival and body-
weight were recorded for 60 days.
Statistical analyses
Data are represented as mean ± SEM of three or four
independent experiments. Student’s t-test was per-
formed to determine statistical significance between
two groups using GraphPad Prism 5.0 (San Diego, CA).
Survival data are presented as Kaplan-Meier survival
curves, and differences between groups were analyzed
by the log-rank test using GraphPad Prism 5.0 (San
Diego, CA). A P value < 0.05 was considered to be sta-
tistically significant.
Results
L2H17 shows selective cytotoxic effect on colon cancer
cells
We screened the cytotoxic effect of L2H17, L40H37,
L6H21, and L48H37 in both human and mouse colon
cancer cells through MTT assay. Curcumin, a structure
analogue of chalcone derivatives with chemopreventive ef-
fect against colon carcinogenesis, was used as the positive
control in the screening [16–18]. As shown in Fig. 1, treat-
ment of these four chalcone derivatives dose-dependently
reduced cell viability in SW620 (Fig. 1b), HCT 116 (Fig. 1c),
and CT26.WT (Fig. 1d), with IC50 values much lower than
those of curcumin. Among them, L48H37 exhibited the
most potent cytotoxic effect against all tested colon cancer
cell lines (IC50 value of 1.752 μM in SW620, IC50 value of
1.899 μM in HCT116, and IC50 value of 1.99 μM in
CT26.WT). An important attribute of an effective antican-
cer drug is cancer selectivity in its cytotoxic effect. Thus,
we also screened the cytotoxic effect of these compounds
against human hepatocyte cell line, HL-7702. As shown in
Fig. 1e, only compound L2H17 exhibited low toxicity effect
in HL7702, with an IC50 value of 173 μM, which is 10
times higher than that of curcumin. These results, there-
fore, suggest that L2H17 exhibits a certain level of colon
cancer selectivity and safety in terms of its cytotoxic effect
in vitro.
To further verify the anti-cancer properties of L2H17,
the RT-CES system was used to test the inhibitory effect
on the proliferation of CT26.WTcells. After the CT26.WT
cells were seeded in E-plates for 24 h, cells were then
treated with L2H17 or curcumin in various concentrations
for 100 h, and the cell growth curves were recorded and
analyzed by the RT-CES system. As shown in Fig. 2a, a
strong inhibition in cell viability was observed in a dose-
dependent manner during 0-76 h after L2H17 treatment.
Similar to the result from Fig. 1d, L2H17 exhibited com-
parative anti-proliferation effect compared to curcumin
(Fig. 2b).
Colony formation ability characterizes the independent
survival ability and environmental adaptability of cancer
cells, and to a certain extent, can reflect the tumorigen-
icity after tumor cell metastasis. We then investigated
the effect of L2H17 on the clonogenic survival ability of
CT26.WT cells by plate colony formation assay. As
shown in Fig. 2c and 2d, similar to curcumin, L2H17
dose-dependently inhibited the clonogenic survival
ability of CT26.WT after seven days of treatment. In
summary, we confirm that L2H7 showed potent in-
hibitory effect on colon cancer cell growth in vitro
and may be a potential candidate for the treatment of
colon cancer.
L2H17 induced a G0/G1 cell cycle arrest and apoptosis in
CT26.WT cells
Curcumin has been reported to exhibit its anti-cancer
effect through its G0/G1 arrest effect [19]. Thus, we
also examined the effect of L2H17 treatment on cell
cycle progression by flow cytometry. We found that
L2H17 induced a dose-dependent cell cycle arrest in the
G0/G1 phase of CT26.WT significantly (Fig. 3a & 3b).
After treatment of CT26.WT with L2H17 at the
concentration of 30 μM for 24 h, G0/G1-phase cells
were increased to 72.73 ± 4.125 % (P <0.001 v.s. DMSO
control), which is comparative to that of curcumin-
treated group (69.17 ± 8.541 %).
We also examined whether L2H17 could induce apop-
tosis in CT26.WT cells. CT26.WT cells were treated with
L2H17 (1, 3, 10, or 30 μM) or curcumin (30 μM) for 48 h,
and then stained with Annexin V and PI for apoptosis ana-
lysis using flow cytometry. As shown in Fig. 3c & 3d,
exposure of CT26.WT to L2H17 resulted in a significant
dose-dependent increase in early (Annexin V+, PI−) and late
apoptotic cells (Annexin V+, PI+). At the dose of 10 μM,
there was a 48.0-fold (P < 0.0001) increase in the population
of CT26.WT cells undergoing apoptosis compared to the
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vehicle control cells (DMSO group). Similar apoptosis
index patterns were obtained when CT26.WT cells were
exposed to curcumin.
In order to further confirm the apoptotic induction
effects of L2H17, the expression of apoptosis-related
proteins was examined using western blot. As shown in
Fig. 4a–4c, CT26.WT exposed to L2H17 for 48 h
showed a dose-dependent reduction in the level of anti-
apoptotic Bcl-2 protein, with a concomitant increase in
the level of pro-apoptotic Bax and the Bax/Bcl-2 ratio,
compared with the control cells (Fig. 4d). Moreover, the
expression of procaspase-3 was clearly decreased, while
cleaved caspase-3 increased notably, with a concomitant
increased cleaved caspase-3/ procaspase-3 ratio (Fig. 4e
& 4f ). PARP-1 can be inactivated by caspase cleavage,
which is considered to be a marker of apoptosis. As
shown in Fig. 4a & 4g, cleaved PARP-1 was induced
dose-dependently after L2H17 treatment. Similar results
were also found in the curcumin-treated group (Fig. 4).
All these data indicated that L2H17 may exert its
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Fig. 2 L2H17 suppressed cell growth of CT26.WT cells. After the CT26.WT cells were seeded in E-plates for 24 h, cells were then treated with L2H17
(a) or curcumin (b) in various concentrations (1, 3, 10, 30 or 100 μM) for 100 h. The cell growth curves were recorded and analyzed by the RT-CES system
(Acea Biosciences Inc., San Diego, CA). (c) Cells were exposed to various concentrations of L2H17 (1, 3, or 10 μM) for 7 days followed by clonogenic
assay. Curcumin (10 μM) or DMSO (3 μL) was added as the positive and negative controls, respectively. Visualized colonies were then photographed
and calculated. The data were obtained from three independent experiments performed in triplicate. And the representative photos were shown. (d) The
calculated colonies were presented as mean ± SEM. The indicated differences are significant ** P< 0.01, *** P< 0.001, and **** P< 0.0001, t-test, compared
to the DMSO-treated group
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L2H17 decreased cell migration and invasion of CT26.WT
cells
To study the inhibitory effects of L2H17 in cell migra-
tion, we adopted a scratch wound model in the pres-
ence of mitomycin C which inhibited cell proliferation.
Wound areas were marked and photographed at 0, 24,
and 48 h, respectively. As shown in Fig. 5a and 5b, the
mobility of CT26.WT cells decreased to 16.18 % (24 h)
and 8.38 % (48 h) in L2H17-treated group (P < 0.0001),
and 11.82 % (24 h) and 9.84 % (48 h) in curcumin-
treated group (P < 0.0001), respectively.
We then examined the effect of L2H17 on the invasive-
ness of CT26.WT cells using the Matrigel invasion assay
as described in Methods. As shown in Fig. 5c & 5d,
L2H17-treated cells markedly decreased their adhesive
ability in a dose-dependent manner compared to the
Fig. 3 L2H17 induced cell cycle arrest and apoptosis in CT26.WT cells. (a) CT26.WT cells were treated with L2H17 (1, 3, 10, or 30 μM) or curcumin
(30 μM) for 24 h, and the cell cycle distribution was analyzed by the cytometry (Becton Dickinson FACSCalibor, BD Biosciences, Franklin Lakes, NJ).
The data were obtained from four independent experiments performed in triplicate. And the representative histogram of the cell cycle distribution
was shown. (b) The mean of the four values was calculated, and the percentages of cells in Sub-G0/G1, S and G2/M phases are shown. (c) The effects
of L2H17 and curcumin on the induction of apoptosis in CT26.WT cells. CT26.WT cells were treated with DMSO or the indicated concentration
of L2H17 (1, 3, 10, or 30 μM) or curcumin (30 μM) for 48 h, and then stained with Annexin V and PI, followed by detection using flow cytometry.
The data were obtained from four independent experiments performed in triplicate. Representative data are shown (c), and the percentages of
cells with early apoptosis (d) are shown. Data are presented as the mean ± SEM. The indicated differences are significant * P <0.05, **P < 0.01,
***P < 0.001, and ****P < 0.0001, t-test, compared to the DMSO-treated group
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Fig. 4 The effects of L2H17 on the expression of apoptosis related proteins in CT26.WT cells. (a) CT26.WT cells were incubated with L2H17 (0, 3, 10, or
30 μM) or curcumin (30 μM) for 48 h. The total protein was extracted and the expression of Bcl-2, Bax, caspase-3 and PARP was examined by western
blot. GAPDH was shown as the control of equal loading. Data shown are representative of three independent experiments. (b-g) The histograms of the
relative density of Bcl-2 (b), Bax (c), Bax/Bcl (d), Cleaved Caspase-3 (e), Cleaved caspase-3/pro-caspase (f), and Cleaved PARP (g) are shown. The indicated
differences are significant * P <0.05, ** P< 0.01, and *** P< 0.001, t-test, L2H17-treated compared to the DMSO-treated group; # P <0.05, ## P< 0.01, and
### P < 0.001, t-test, curcumin-treated compared to the DMSO-treated group
Fig. 5 (See legend on next page.)
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DMSO control group (P < 0.05). In addition, curcumin
showed similar effects on cell migration and invasion.
E-cadherin, a member of the classic cadherin family, is
frequently associated with dedifferentiation and invasion
in a variety of human cancers. Loss of E-cadherin in can-
cer cells is often associated with markers of “epithelial-to-
mesenchymal transition” (EMT), including colon cancer
cells [20]. In order to figure out the mechanism for the
inhibitory effect of L2H17 in colon cancer cell migration
and invasion, we measured the expression of E-cadherin
in L2H17-treated CT26.WT cells. As shown in Fig. 5e,
L2H17 treatment significantly increased the E-cadherin
expression level in CT26.WTcells.
L2H17 inactivated NF-κB signaling of CT26.WT cells
A potential role for NF-κB in the initiation, promotion
and progression of tumor, including stomach cancer
[21], colon cancer [22], pancreatic cancer [23], liver can-
cer [24], lung cancer [25], has been already evident. The
degradation of IκB-α, which is an inhibitory factor of
NF-κB, leads to NF-κB activation via promoting p65
translocation from the cytosol to nucleus. In order to
explore the possible mechanism through which L2H17
exerts its anti-cancer effect, we examined the degrad-
ation of IκB-α after L2H17 treatment. CT26.WT cells
were treated with L2H17 (10 μM) for indicated times, or
treated with indicated concentration of L2H17 (1, 3, 10, or
30 μM) for 30 min. As shown in Fig. 6a & 6c, L2H17 treat-
ment time-dependently and dose-dependently inhibited
the degradation of IκB-α. Also, as evident from the Fig. 6d,
L2H17 treatment reduced nuclear p65 protein level, par-
tially demonstrating the potential molecular mechanism
underlying the effect of L2H17 on colon cancer is through
its inhibition of NF-κB signaling.
Previous studies indicate that PI3K signaling pathways
are implicated in cancer invasion [26]. Thus, we then
examined whether the invasion-suppressing activity of
L2H17 is related to attenuation of the Akt expression
using western blot analysis. As shown in Fig. 6b & 6e,
L2H17 significantly reduced Akt activation in both a
time-dependent and a dose-dependent manner. These
data suggest that attenuation of the Akt signaling path-
way by L2H17 presumably leads to a reduced level of
cell invasion.
L2H17 possessed anti-tumor activity in vivo
Finally, we evaluated the anti-tumor effects of L2H17 in
vivo. The mice injected with CT26.WT cells were
administered orally with either L2H17 (25 mg/kg/day or
50 mg/kg/day), curcumin (50 mg/kg/day or 100 mg/kg/
day) or vehicle (1 % CMC-Na) for 60 days. After injec-
tion with 3 × 105 murine CT26.WT cells, all animals
developed multiple lung metastases (data not shown).
However, as shown in Fig. 7a, treatment of L2H17, at
both low and high dosage, significantly extends the
survival in the tumor mice (P < 0.01). Curcumin exhib-
ited its anti-tumor effects only at the dose of 100 mg/kg/
day (P < 0.05). Besides, there is no significant differences
in survival and body weight change among the non-
tumor curcumin (100 mg/kg/day), non-tumor L2H17
(50 mg/kg/day), and non-tumor CMC-Na (1 % CMC-
Na/day), which indicating that no significant side effects
of curcumin and L2H17 were found at these therapeutic
doses (Fig. 7a & 7b).
Discussion
A lot of literatures have demonstrated that chalcones
possess chemopreventive and anti-tumoural activities
among several interesting biological properties [27, 28].
Juan Rodrigues et al. have reported the potent effects of
new 4-maleamic acid and 4-maleamide peptidyl chal-
cone derivatives against human prostate cancer in vitro
and in vivo [29]. It has been also reported that derivatives
of hydroxychalcones showed effective cytotoxicity against
melanoma cells B16-10 [30]. More recent studies have
shown the use of Flavokawain B, a kava chalcone, as a
chemotherapeutic and chemopreventive compound [31].
Especially, chalcone derivatives of 2-acetyl thiophene show
(See figure on previous page.)
Fig. 5 L2H17 inhibited cell migration and invasion of CT26.WT cells. CT26.WT cells were seeded and allowed to adhere overnight. The next day, the
“reference line” was drawn at the bottom of each plate. After washed with PBS, the cells were treated with L2H17 (10 μM), curcumin (10 μM) or DMSO
(vehicle control) in the presence of mitomycin C for indicated times (24 or 48 h). (a) Representative photomicrographs are shown from one out of four
independent cell migration experiments. On 0 h images, the “reference line” was drawn to represent the starting points for CT26.WT cells. (b) The
mobility of CT26.WT cells was calculated for L2H17- or curcumin-treated groups as compared with the DMSO-treated (vehicle control) group for each
experiment in different fields. The bar chart represents means (± SEM) of four independent experiments. CT26.WT cells were seeded in the transwell
plate that was coated with Matrigel. Then the cells were treated with either L2H17 (1, 3, or 10 μM) or curcumin (1, 3, or 10 μM) for 24 h. And then the
invasion cells were fixed, stained and viewed under a light microscope (×100; Nikon, Tokyo, Japan). (c) Representative photomicrographs of
DMSO control (vehicle control), L2H17- and curcumin-treated invading cells are shown from one out of four independent. (d) The numbers of
invading cells in L2H17- or curcumin-treated groups as compared with the DMSO-treated (vehicle control) group for each experiment in at
least 15 representative microscopic fields. (e) CT26.WT cells were treated with L2H17 (10 μM) for 12 h. Then the total protein was extracted
and the expression of E-cadherin were detected by Western blot analysis. The column figures show the normalized optical density from the data from
three independent experiments. The bar chart represents means (± SEM) from one out of three independent experiments. The indicated
differences are significant *P <0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, t-test, L2H17-treated compared to the DMSO-treated group;
#P <0.05, ##P < 0.01, ###P < 0.001, and ####P < 0.0001, t-test, curcumin-treated compared to the DMSO-treated group
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the cytotoxic and apoptotic effects on human colon cells
[32]. Based on the potent pharmacological properties of
chalcones, we prepared four synthetic chalcones to inves-
tigate their anti-cancer effects on colon cancer cell lines
by MTT assay. MTT assay is able to measure cell meta-
bolic activity mostly throughout mitochondria metabolism
[33]. Our data show that treatment of these four synthetic
chalcone derivatives dose-dependently reduced cell viabil-
ity in SW620 (Fig. 1b), HCT 116 (Fig. 1c), and CT26.WT
(Fig. 1d), with IC50 values much lower than those of cur-
cumin. An attractive candidate as an anticancer agent is
characterized by a high degree of cancer-selectivity in its
cytotoxic effect. In our results, L2H17, with its potent
cytotoxic effect on cancerous cells and the weakest effect
on noncancerous cells (Fig. 1), was further investigated for
its effect on the carcinogenesis of colon cancer. In
addition, RT-CES assay and colony formation assay dem-
onstrated that L2H17 presents as good inhibitory effects
on colon cancer cell growth as curcumin (Fig. 2).
We then investigated cell apoptosis, cell cycle and the ex-
pression of the apoptotic related proteins following L2H17
treatments. Our data showed that L2H17, as well as curcu-
min, induced prominent cell apoptosis in CT26.WT (Figs. 2
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Fig. 6 NF-κB and Akt pathways may be involved in the anti-cancer effects of L2H17. CT26.WT cells were treated with L2H17 (10 μM) for indicated
times (0, 10, 30, 60, 120, or 240 min, a & b) or treated with indicated concentrations of L2H17 (1, 3, 10, or 30 μM, c & d) for 30 min. Then the total
protein was extracted and the expression of IκB-α (a,c), p-Akt (b,e) proteins were detected by Western blot analysis. (d) CT26.WT cells were treated with
L2H17 (10 μM) or vehicle control (DMSO) for 1 h. Then the cells were harvested and lysed, nuclear extracts were prepared, and p65 expression levels in
the nucleus were measured by Western blot assay. The column figures show the normalized optical density from the data from three independent
experiments. Data are presented as the mean ± SEM. The indicated differences are significant * P <0.05, ** P < 0.01, and *** P < 0.001, t-test, compared
to the DMSO-treated group
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only in preventing the development and progression of
premalignant colonic epithelial cells to colon tumors but
also in resistance of tumors to conventional cancer therap-
ies [34]. In our study, L2H17 and curcumin significantly in-
crease the expression of Bax and suppress the expression
of Bcl-2. Interestingly, both agents induced the activation
of procaspase-3, which was associated with a significant in-
crease in the cleavage and activation of PARP, a target pro-
tein of caspase-3 (Fig. 4e–g). The changes are consistent
with the levels of Bcl-2 and Bax expression, supporting the
conclusion that the intrinsic pathway is the major mechan-
ism of apoptosis following L2H17 exposure (Fig. 4b–4d).
Additionally, the G0/G1 arrest of CT26.WT upon the two
compounds treatment partly explained their growth sup-
pression on colon cancer cell (Fig. 3a–3b).
Metastasis, proceeding through several consecutive
steps including neovascularization, migration, intravasa-
tion, circulation of lymphatic or vascular channels,
extravasation and ultimate metastatic colonization is the
most malignant feature during cancer progression and
accounts for almost 90 % of mortality [35]. Since inva-
sion and migration are a critical event in cancer progres-
sion and especially in metastasis, the inhibitory effect of
L2H17 on cell invasion and migration was evaluated.
Our results showed that L2H17 exhibits similar effects
on cell migration and invasion as compared to that of
curcumin via increasing the expression of E-cadherin in
CT26.WT cells (Fig. 5).
Activated p-Akt, existing in most cancer cells, is a major
anti-apoptotic pathway which is frequently hyperactivated
in most cancers and is able to promote cell growth and
survival by activating its downstream substrates. In
addition, activated p-Akt is shown to be associated with
various tumor promotion and progression by regulating its
downstram pathways such as NF-κB [36]. The activation of
NF-κB pathway is a crucial event in tumor growth and
progression [37]. In addition to inhibition of apoptosis,
activated NF-κB may control cell cycle progression by
regulating the expression of important cell cycle regulatory
proteins such as cyclin D1 andcyclin dependent kinase 2
(CDK2), further contributing to the tumour growth [38].
Potentiation of cancer cell migration and invasion also
explains the role of NF-κB in tumor promotion and
progression [38]. In the present study, L2H17 dose-
dependently inhibited the degradation of IκB and the
phosphorylation of Akt, indicating the inhibition of
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Fig. 7 Treatment of L2H17 inhibited the tumorigenesis of CT26.WT cells in BALB/c mice. CT26.WT cells were harvested and injected intravenously
into the BALB/c mice (3 × 105 cells/mouse). Simultaneously, the mice were administered orally with either L2H17 (25 mg/kg/day or 50 mg/kg/day),
curcumin (50 mg/kg/day, 100 mg/kg/day) or vehicle control (1 % CMC-Na) for 60 days, while the tumor-free control mice were treated with the L2H17
(50 mg/kg/day), curcumin (100 mg/kg/day), or 1 % CMC-Na as the negative control (n = 9 in each group). Shown are survival (a) and body weight
change (b). The indicated differences are significant *P <0.05 and **P < 0.01, log-rank test, compared to the CT26.WT + CMC-Na-treated group
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L2H17 on the activation of NF-κB and Akt pathway,
which is consistent with our initial results performed
by MTT assay, colony formation assay, flow cytometry
and cell migration and invasion assay (Fig. 6).
L2H17 showed some obvious advantages over curcu-
min, the known potent chemopreventive agent against
colon cancer, in the inhibition of conlon cancer cells in
vitro and in vivo. Despite showing the similar cytotoxic
effect on colon cancer cell lines, L2H17 is much more
moderate on the noncancerous HL7702 than curcumin
(Fig. 1), indicating its low toxicity and exceptional safety.
Although there is no significant toxicity in both L2H17-
treated and curcumin-treated group in vivo (Fig. 7a), the
statistically significant dosage of L2H17 is lower than
curcumin, 25 mg/kg/day and 100 mg/kg/day, respect-
ively (Fig. 7).
Conclusions
Our results show the potent chemopreventive effect and
molecular mechanisms of L2H17 on colon cancer both
in vitro and in vivo, and provide us a promising agent,
which is expected to be developed into an effective
therapeutic drug against colon cancer. Further experi-
ments are surely needed to explore the direct targets of
L2H17 on colon cancer cells.
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